The Ministry of Health has approved Order SND/1118/2025, of 6 October, which updates the reference price system for medicines in the National Health System in 2025. The order, which incorporates the amendments introduced in the regulation of this system by Law 7/2025, of July 28, establishing the State Public Health Agency (excluding medicines derived from human plasma and orphan drugs from this system), establishes new reference groups and prices, reviews the existing ones, and suppresses those that no longer meet the regulatory requirements.
The contents of the order by annexes and its main novelties are summarized below.
Annex 1: Medicines dispensable in pharmacies
Annex 1 lists the reference groups of dispensable presentations by official prescription or dispensing order, with an indication of the industrial reference price and the reference VAT retail price of each presentation.
The groups numbered from F500 to F513 are newly created.
Annex 2: Hospital-use medicines and clinical packaging
Annex 2 lists the reference groups of presentations of medicines in the hospital setting and presentations in clinical packaging, with their industrial reference price.
The groups numbered from P195 to P205 and S108 are newly created.
Annex 3: Reference price for each group and cost/treatment/day ("CTD")
For information purposes, Annex 3 connects all reference groups to the reference price of each group and identifies the presentation whose CTD determines that price. It also includes information on the defined daily doses used to calculate the CTD, as well as the identification of groups formed by the existence of biosimilars and those constituted without generics or biosimilars.
Annex 4: Removed reference groups
Annex 4 includes the list of reference groups suppressed because they no longer meet the conditions required for their establishment or for the reasons provided for in the applicable regulations.
Annex 5: Galenic innovations temporarily excluded from the system
Annex 5 lists the presentations declared as galenic innovations of therapeutic interest prior to the entry into force of Royal Decree-Law 16/2012, temporarily excluded from the reference price system and whose declaration expires after the date of effect of the order.
Annex 6: Presentations without group formation
Annex 6 lists the presentations and licenses for which no reference group has been formed in accordance with article 3.2 of Royal Decree 177/2014.
Annex 7: Integration and industrial reference prices
Annex 7 details the presentations of medicinal products, the reference group in which they will be integrated, and the industrial reference price group for each one.
Entry into force
The laboratories must supply according to these new prices starting October 14, 2025. Distributors must apply the new distributor sale price after twenty (20) calendar days. Pharmacies must dispense medicines at the new PVP starting December 1st, 2025.
Don’t miss our content
Subscribe